Compare · NVO vs PHVS
NVO vs PHVS
Side-by-side comparison of Novo Nordisk A/S (NVO) and Pharvaris N.V. (PHVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PHVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 83.2x PHVS ($2.20B).
- Over the past year, NVO is down 45.7% and PHVS is up 75.6% - PHVS leads by 121.2 points.
- PHVS has been more active in the news (13 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 13 for PHVS).
- Company
- Novo Nordisk A/S
- Pharvaris N.V.
- Price
- $41.01-4.51%
- $31.68+1.64%
- Market cap
- $183.15B
- $2.20B
- 1M return
- -10.44%
- +6.87%
- 1Y return
- -45.66%
- +75.58%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 8
- 13
- Recent ratings
- 25
- 13
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Pharvaris N.V.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks; and PHVS719, a prophylactic extended-release tablet for HAE patients. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is headquartered in Leiden, the Netherlands.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest PHVS
- Principal Accounting Officer Nijdam Anna sold $82,425 worth of shares (2,670 units at $30.87), decreasing direct ownership by 5% to 46,275 units (SEC Form 4)
- Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
- Director Monges Viviane sold $292,853 worth of shares (9,667 units at $30.29), decreasing direct ownership by 64% to 5,500 units (SEC Form 4) to satisfy tax liability
- Principal Accounting Officer Nijdam Anna exercised 7,330 shares at a strike of $20.00 and sold $225,055 worth of shares (7,330 units at $30.70) (SEC Form 4) to satisfy withholding obligation
- CFO / CLO Nassif David W. sold $303,076 worth of shares (10,000 units at $30.31), decreasing direct ownership by 8% to 120,300 units (SEC Form 4) to satisfy withholding obligation
- Director Bjork Elisabeth exercised 10,000 shares at a strike of $8.05 and sold $293,166 worth of shares (10,000 units at $29.32) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form 4 filed by Chief Executive Officer Modig Berndt
- SEC Form 144 filed by Pharvaris N.V.
- Chief Executive Officer Modig Berndt sold $66,977 worth of shares (2,292 units at $29.22) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 137,500 units (SEC Form 4)
- SEC Form 144 filed by Pharvaris N.V.